[1]尹世杰,王 跃,程丽敏.基于GEO差异基因分析及网络药理学探究真人养脏汤治疗活动性溃疡性结肠炎的分子机制研究[J].医学信息,2023,36(03):70-76.[doi:10.3969/j.issn.1006-1959.2023.03.015]
　YIN Shi-jie,WANG Yue,CHENG Li-min.A Study on Mechanism of Zhenren Yangzang Decoction in the Treatment of Active Ulcerative Colitis Based on GEO Difference Analysis and Network Pharmacology[J].Journal of Medical Information,2023,36(03):70-76.[doi:10.3969/j.issn.1006-1959.2023.03.015]
点击复制

基于GEO差异基因分析及网络药理学探究真人养脏汤治疗活动性溃疡性结肠炎的分子机制研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年03期
页码:
70-76
栏目:
生物信息学
出版日期:
2023-02-01

文章信息/Info

Title:
A Study on Mechanism of Zhenren Yangzang Decoction in the Treatment of Active Ulcerative Colitis Based on GEO Difference Analysis and Network Pharmacology
文章编号:
1006-1959（2023）03-0070-07
作者:
尹世杰; 王 跃; 程丽敏
（1.黑龙江中医药大学第一临床医学院，黑龙江 哈尔滨 150000；2.黑龙江中医药大学第一附属医院肛肠科，黑龙江 哈尔滨 150000）
Author(s):
YIN Shi-jie; WANG Yue; CHENG Li-min
(1.The First Clinical Medical College,Heilongjiang University of Traditional Chinese Medicine,Harbin 150000,Heilongjiang,China;2.Department of Anorectal Surgery,the First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine,Harbin 150000,Heilongjiang,China)
关键词:
溃疡性结肠炎; GEO差异基因分析; 网络药理; 真人养脏汤
Keywords:
Ulcerative colitis; GEO differential gene analysis; Network pharmacology; Zhenren Yangzang decoction
分类号:
R285.5；R574.62
DOI:
10.3969/j.issn.1006-1959.2023.03.015
文献标志码:
A
摘要:
目的 通过GEO差异基因分析及网络药理学探究真人养脏汤治疗活动性溃疡性结肠炎的分子机制。方法 从GEO数据库检索溃疡性结肠炎，选择成年人活动期样本，并下载相关样本文件，再以R语言进行差异基因分析，获得相关靶点；从TCMSP数据库检索真人养脏汤各组成有效化合物成份及其对应的相关靶点，提取差异基因与相关药物靶点的交集，在STRING数据库中查询其蛋白互相作用网络（PPI），使用Cytoscape软件构建“药物-成分-靶点”调控网络并提取核心靶点，再利用R语言对其进行基因本体（GO）和京都基因与基因组百科全书（KEGG）富集分析。结果 筛得差异基因1097个，查得真人养脏汤中有效成分141个，对应靶点258个；从其中36个交集靶点中筛选出PPI核心靶点10个，关键靶点涉及白介素6（IL-6）、肿瘤坏死因子（TNF）、基质金属蛋白酶9（MMP9），基因显著富集于对脂多糖反应、受体配体活动、信号受体激活因子活性等分子功能。通路主要富集于肿瘤坏死因子（TNF）、白介素17（IL-17）、核转录因子κB（NF-κB）信号通路。结论 真人养脏汤治疗UC具有多靶点、多通路等特点，尤其在炎性反应通路及免疫相关通路发挥重要作用。
Abstract:
Objective To explore the molecular mechanism of Zhenren Yangzang Decoction in the treatment of active ulcerative colitis by GEO differential gene analysis and network pharmacology.Methods Ulcerative colitis was retrieved from the GEO database, and the active samples of adults were selected. The relevant sample files were downloaded, and the differential gene analysis was performed in R language to obtain the relevant targets. The effective compound components of Zhenren Yangzang decoction and their corresponding related targets were retrieved from the TCMSP database, and the intersection of differential genes and related drug targets was extracted. The protein interaction network (PPI) was queried in the STRING database. Cytoscape software was used to construct the “drug-component-target” regulatory network and extract the core targets, and then R language was used for gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis.Results A total of 1097 differential genes were screened, and 141 effective components and 258 corresponding targets were found in Zhenren Yangzang decoction. Ten PPI core targets were screened from 36 intersection targets. The key targets involved interleukin 6 (IL-6), tumor necrosis factor (TNF), and matrix metalloproteinase 9 (MMP9). The genes were significantly enriched in molecular functions such as lipopolysaccharide response, receptor ligand activity, and signal receptor activator activity. The pathways were mainly enriched in tumor necrosis factor (TNF), interleukin 17 (IL-17), and nuclear transcription factor κB (NF-κB) signaling pathways.Conclusion Zhenren Yangzang decoction has the characteristics of multi-target and multi-pathway in the treatment of UC, especially in the inflammatory response pathway and immune-related pathway.

参考文献/References:

[1]张声生,沈洪,郑凯,等.溃疡性结肠炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(8):3585-3589.[2]Kaplan GG,Windsor JW.The four epidemiological stages in the global evolution of inflammatory bowel disease[J].Nat Rev Gastroenterol Hepatol,2021,18(1):56-66.[3]何清湖.中西医结合外科学(新世纪第三版)[M].北京,中国中医药出版社,2016(8):497-506.[4]李冀,连建伟.方剂学(新世纪第四版)[M].北京:中国中医药出版社,2016(8):152-153.[5]Adams SM,Bornemann PH.Ulcerative colitis[J].Am Fam Physician,2013,87(10):699-705.[6]司丽君,王雪,王林林,等.槲皮素的抗炎免疫及部分机制研究[J].中国医药导报,2021,18(27):26-29,34.[7]周霄楠,韩超,宋鹏琰,等.木犀草素和槲皮素体外抗炎作用研究[J].动物医学进展,2017,38(10):56-61.[8]刘萍,卞艺斐,钟佳,等.槲皮素对PGN诱导的大鼠肠黏膜微血管内皮细胞炎性损伤的作用及其机制研究[J].中国兽医杂志,2020,56(5):54-57.[9]曲一帆.山奈酚缓解小鼠溃疡性结肠炎的肠道微生态机理研究[D].呼和浩特:内蒙古医科大学,2021.[10]Fernández J,de la Fuente VG,García MTF,et al.A diet based on cured acorn-fed ham with oleic acid content promotes anti-inflammatory gut microbiota and prevents ulcerative colitis in an animal model[J].Lipids Health Dis,2020,19(1):28.[11]杨海静.油酸和1,25(OH)2D3对人血管平滑肌细胞TLR4基因及炎症因子IL-6、IL-8和MCP-1表达的调节作用[D]. 兰州:兰州大学,2012.[12]Gu P,Theiss A,Han J,et al.Increased Cell Adhesion Molecules, PECAM-1,ICAM-3,or VCAM-1, Predict Increased Risk for Flare in Patients With Quiescent Inflammatory Bowel Disease[J].J Clin Gastroenterol,2017,51(6):522-527.[13]Buisson A,Vazeille E,Minet-Quinard R.Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases[J].J Clin Gastroenterol,2018,52(7):e53-e62.[14]Lucafò M,Pugnetti L,Bramuzzo M.Long Non-Coding RNA GAS5 and Intestinal MMP2 and MMP9 Expression: A Translational Study in Pediatric Patients with IBD[J].Int J Mol Sci,2019,20(21):5280.[15]Sandborn WJ,Bhandari BR,Randall C.Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease[J].J Crohns Colitis,2018,12(9):1021-1029.[16]Qiu P,Liu L,Fang J.Identification of Pharmacological Autophagy Regulators of Active Ulcerative Colitis[J].Front Pharmacol,2021,12:769718.[17]Vermeire S,Sandborn WJ,Danese S.Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial[J].Lancet,2017,390(10090):135-144.[18]Sandborn WJ,Lee SD,Tarabar D.Phase Ⅱ evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study[J].Gut,2018,67(10):1824-1835.[19]Sipponen T,F?覿rkkil?覿 M,Kolho KL.Uusia vaihtoehtoja tulehduksellisten suolistosairauksien hoitoon [J].Duodecim,2014,130(14):1391-1398.[20]Vetuschi A,Pompili S,Gaudio E.PPAR-γ with its anti-inflammatory and anti-fibrotic action could be an effective therapeutic target in IBD[J].Eur Rev Med Pharmacol Sci,2018,22(24):8839-8848.[21]Venkataraman B,Almarzooqi S,Raj V.α-Bisabolol Mitigates Colon Inflammation by Stimulating Colon PPAR-γ?Transcription Factor: In Vivo and In Vitro Study[J].PPAR Res,2022,2022:5498115.[22]Xu C,Wu Y,Liu N.Osteopontin in autoimmune disorders: current knowledge and future perspective[J].Inflammopharmacology,2022,30(2):385-396.[23]Komine-Aizawa S,Masuda H,Mazaki T,et al.Plasma osteopontin predicts inflammatory bowel disease activities[J].Int Surg,2015,100(1):38-43.[24]Karaman S,Lepp?覿nen VM,Alitalo K.Vascular endothelial growth factor signaling in development and disease[J].Development,2018,145(14):dev151019.[25]Whitney JE,Silverman M,Norton JS.Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor as Novel Biomarkers for Poor Outcomes in Children With Severe Sepsis and Septic Shock[J].Pediatr Emerg Care,2020,36(12):e715-e719.[26]陈金湖.沙利度胺对大鼠实验性结肠炎血管内皮生长因子表达的影响[D].福州:福建医科大学,2017.[27]Levin AD,Wildenberg ME,van den Brink GR.Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease[J].J Crohns Colitis,2016,10(8):989-997.[28]Verstockt B,Deleenheer B,Van Assche G,et al.A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases[J].Expert Opin Drug Saf,2017,16(7):809-821.[29]Sakthivel KM,Guruvayoorappan C.Protective effect of Acacia ferruginea against ulcerative colitis via modulating inflammatory mediators, cytokine profile and NF-κB signal transduction pathways[J].J Environ Pathol Toxicol Oncol,2014,33(2):83-98.[30]周璐.TLR4-MyD88-NF-kB信号通路在溃疡性结肠炎中的表达及临床意义[D].郑州:郑州大学,2021.[31]陈爱莹.溃克灵改良方通过TLR4/MyD88/NF-kB信号通路抑制小鼠结肠炎的作用机制研究[D].南京:南京中医药大学,2021.[32]Gao W,Xiong Y,Li Q,et al.Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics[J].Front Physiol,2017,8:508.

相似文献/References:

[1]杜丽君.穴位埋线疗法联合口服美沙拉嗪治疗溃疡性结肠炎的 护理分析[J].医学信息,2018,31(05):172.[doi:10.3969/j.issn.1006-1959.2018.05.063]
　DU Li-jun.Nursing Analysis of Acupoint Catgut Embedding Therapy Combined with Oral Mesalazine in the Treatment of Ulcerative Colitis[J].Journal of Medical Information,2018,31(03):172.[doi:10.3969/j.issn.1006-1959.2018.05.063]
[2]张君红,李洪梅,井 洁,等.溃疡性结肠炎中西医结合治疗研究[J].医学信息,2018,31(09):59.[doi:10.3969/j.issn.1006-1959.2018.09.019]
　ZHANG Jun-hong,LI Hong-mei,JING Jie,et al.Study on the Treatment of Ulcerative Colitis with Integrated Traditional Chinese and Western Medicine[J].Journal of Medical Information,2018,31(03):59.[doi:10.3969/j.issn.1006-1959.2018.09.019]
[3]李 伟,徐 伟.溃疡性结肠炎中医干预治疗研究[J].医学信息,2022,35(09):62.[doi:10.3969/j.issn.1006-1959.2022.09.015]
　LI Wei,XU Wei.Study on Traditional Chinese Medicine Intervention Treatment of Ulcerative Colitis[J].Journal of Medical Information,2022,35(03):62.[doi:10.3969/j.issn.1006-1959.2022.09.015]
[4]汤胜男,赵党生,王凤仪,等.芍药汤治疗溃疡性结肠炎的研究[J].医学信息,2019,32(15):3.[doi:10.3969/j.issn.1006-1959.2019.15.002]
　TANG Sheng-nan,ZHAO Dang-sheng,WANG Feng-yi,et al.Study on Treating Ulcerative Colitis with Shaoyao Decoction[J].Journal of Medical Information,2019,32(03):3.[doi:10.3969/j.issn.1006-1959.2019.15.002]
[5]宋 崟,张 科.基于生物信息学方法探究溃疡性结肠炎的关键基因和通路[J].医学信息,2022,35(16):13.[doi:10.3969/j.issn.1006-1959.2022.16.003]
　SONG Yin,ZHANG Ke.Key Genes and Pathways of Ulcerative Colitis Based on Bioinformatics[J].Journal of Medical Information,2022,35(03):13.[doi:10.3969/j.issn.1006-1959.2022.16.003]
[6]华 琳,陈元旺,唐 静,等.溃疡性结肠炎患者外周血Tim-4 mRNA表达水平的变化及意义[J].医学信息,2019,32(21):161.[doi:10.3969/j.issn.1006-1959.2019.21.054]
　HUA Lin,CHEN Yuan-wang,TANG Jing,et al.Changes and Significance of Tim-4 mRNA Expression in Peripheral Blood of Patients with Ulcerative Colitis[J].Journal of Medical Information,2019,32(03):161.[doi:10.3969/j.issn.1006-1959.2019.21.054]
[7]徐 杰.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的效果比较[J].医学信息,2020,33(04):151.[doi:10.3969/j.issn.1006-1959.2020.04.049]
　XU Jie.Comparison of Mesalazine and Sulfasalazine in Treating Ulcerative Colitis[J].Journal of Medical Information,2020,33(03):151.[doi:10.3969/j.issn.1006-1959.2020.04.049]
[8]牙韩清,郑琴芳,何志钧.溃疡性结肠炎相关结直肠癌手术治疗现况[J].医学信息,2020,33(07):44.[doi:10.3969/j.issn.1006-1959.2020.07.014]
　YA Han-qing,ZHENG Qin-fang,HE Zhi-jun.Surgical Treatment of Ulcerative Colitis-related Colorectal Cancer[J].Journal of Medical Information,2020,33(03):44.[doi:10.3969/j.issn.1006-1959.2020.07.014]
[9]王莹洁,戴迟兵.益生菌在炎症性肠病中的应用研究[J].医学信息,2020,33(22):42.[doi:10.3969/j.issn.1006-1959.2020.22.013]
　WANG Ying-jie,DAI Chi-bing.Study on the Application of Probiotics in Inflammatory Bowel Disease[J].Journal of Medical Information,2020,33(03):42.[doi:10.3969/j.issn.1006-1959.2020.22.013]
[10]朱 燕,刘大铭,刘全喜,等.溃疡性结肠炎中医诊疗思路[J].医学信息,2021,34(03):167.[doi:10.3969/j.issn.1006-1959.2021.03.048]
　ZHU Yan,LIU Da-ming,LIU Quan-xi,et al.TCM Diagnosis and Treatment of Ulcerative Colitis[J].Journal of Medical Information,2021,34(03):167.[doi:10.3969/j.issn.1006-1959.2021.03.048]

更新日期/Last Update: 1900-01-01